Company Focus
MBF Therapeutics is an immunotherapeutic animal health company focused on the use its innovative T- Max™ DNA vaccine platform to create disruptive products for infectious disease and cancer. Initial development is focused on highly efficacious, universal vaccines that prevent significant current and new infectious diseases in animals with translational opportunities in humans.
MBFT has assembled an extensive technology platform including multiple check point inhibitors, immunomodulators, adjuvants and delivery systems that work in concert to modulate the immune system, stimulating a durable cell mediated effector and memory response against a broad range of pathogens and cancers.
Market Need
The need for new approaches to vaccine development have never been more critical as demonstrated by the continued worldwide deadly impact of infectious disease on man and animals. Coronavirus (COVID-19, SARS, MERS) and influenza viruses are great examples of on-going pandemic threats due to their ability to mutate and jump from species to species, including humans. African Swine Fever in pigs is one of several serious threats to the world’s food supply. By eliciting a precise and robust T-cell mediated effector and memory immune response, MBFT technology promises a more effective, longer lasting, readily adaptable, universal and straightforward to manufacture vaccine platform - a different and disruptive approach to infectious disease management.
Immunotherapy Assets
- MBFT’s T-Max™ platform includes a portfolio of proprietary gene-based check point inhibitors and immunomodulators that can "turbo-charge" the immune system. This includes in-licensed technology as well as our own Intellectual Property. It also includes our novel antigen selection system that focuses on selecting clinically relevant core antigens that offer robust cross-protection against multiple strains and have the potential to produce "universal" vaccines for certain infectious disease pathogens and cancer types. Two recently completed clinical trials validate our approach.
- A proprietary biodegradable, immunologically inert, non-viral nanoparticle delivery system (CaptaVax™) that targets gene delivery to dendritic and other antigen presenting cells in a safe and efficient manner that allows re-administration and represents a significant near-term income generator in the animal health autogenous vaccine market.
- Pending patent 16/917,899 (USPTO Notice of Allowance issued 5/28/21) provides methods of using DNA and RNA compositions and methods to treat or prevent diseases in humans or livestock/companion animals, including viral diseases and cancers. A PCT application was filed June 10, 2021.